Where we are heading
Certified brain monitoring for neurological care, starting with epilepsy.
Over 40% of people with epilepsy experience cognitive impairment, and cognitive side effects are one of the main reasons anti-seizure medication gets changed. Today those effects are judged from what a patient recalls in a 15-minute consultation.
Axite is developing the Axite App (NeuroJournal) as a certified medical device under the EU Medical Device Regulation (Class IIa) for measuring and displaying cognitive activity, with FDA clearance in the US to follow. That certification opens the same measurement to people with neurological conditions, such as epilepsy, Alzheimer's disease and other forms of dementia, and to the clinics that treat them, with epilepsy as the first indication.